- Home
- IONS vs BOKF Comparison
IONS vs BOKF Comparison
Compare IONS & BOKF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BOKF
- Stock Information
- Founded
- IONS 1989
- BOKF 1910
- Country
- IONS United States
- BOKF United States
- Employees
- IONS N/A
- BOKF N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BOKF Major Banks
- Sector
- IONS Health Care
- BOKF Finance
- Exchange
- IONS Nasdaq
- BOKF Nasdaq
- Market Cap
- IONS 6.8B
- BOKF 6.0B
- IPO Year
- IONS 1991
- BOKF N/A
- Fundamental
- Price
- IONS $70.41
- BOKF $106.19
- Analyst Decision
- IONS Strong Buy
- BOKF Hold
- Analyst Count
- IONS 20
- BOKF 10
- Target Price
- IONS $75.55
- BOKF $115.70
- AVG Volume (30 Days)
- IONS 2.1M
- BOKF 250.6K
- Earning Date
- IONS 10-29-2025
- BOKF 10-20-2025
- Dividend Yield
- IONS N/A
- BOKF 2.15%
- EPS Growth
- IONS N/A
- BOKF 15.57
- EPS
- IONS N/A
- BOKF 8.40
- Revenue
- IONS $944,050,000.00
- BOKF $2,107,001,000.00
- Revenue This Year
- IONS $24.02
- BOKF $6.82
- Revenue Next Year
- IONS $4.06
- BOKF $6.73
- P/E Ratio
- IONS N/A
- BOKF $12.65
- Revenue Growth
- IONS 16.05
- BOKF 5.09
- 52 Week Low
- IONS $23.95
- BOKF $85.08
- 52 Week High
- IONS $74.42
- BOKF $121.58
- Technical
- Relative Strength Index (RSI)
- IONS 63.48
- BOKF 43.04
- Support Level
- IONS $70.47
- BOKF $104.01
- Resistance Level
- IONS $74.42
- BOKF $110.65
- Average True Range (ATR)
- IONS 1.84
- BOKF 3.30
- MACD
- IONS -0.64
- BOKF -0.83
- Stochastic Oscillator
- IONS 37.12
- BOKF 17.08
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About BOKF BOK Financial Corporation
BOK Financial Corp is a financial institution in Oklahoma, and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services, including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking, and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.